This study revealed that the irAEs of PD-1/PD-L1 inhibitors (either as monotherapy or combination therapy) for lung cancer were mainly low grade and suggested that patients with irAEs showed improved effectiveness over patients without irAEs. Here, PDCD1 is linked to lung carcinoma.